AI-generated summary
The authors report a randomized trial of 150 patients with postoperative facial scars, all receiving fractional 1064-nm Nd laser, with a control hydrogel or one of two topical formulations marketed as exosome skin boosters. Both formulations were associated with greater short-term improvements in clinician-rated scar scores and an exploratory optical measure than the control. Patient-reported improvement did not differ significantly between groups, and the human-derived and plant-derived formulations did not differ significantly from each other.
- Participants
- 150
- Who or what was studied
- Patients with postoperative facial scars receiving adjunctive topical formulations with fractional Nd laser treatment
- Wavelengths
- 1064 nm
- Limits stated in the abstract
- Eleven participants were lost to follow-up, outcomes were assessed only 2 weeks after the final session, and the abstract states that no exosome-specific effect, long-term remodeling or long-term safety was established.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on link.springer.com.
Record from PubMed, a service of the National Library of Medicine.
How to read a trial: what to check before relying on this kind of research.
Terms in this paper: Laser, Randomized controlled trial, Control group. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.